Aims: Patients with heart failure (HF) remain often undertreated for multiple reasons, including treatment inertia, contraindications, and intolerance. The OPTIimal PHARMacological therapy for patients with Heart Failure (OPTIPHARM-HF) registry is designed to evaluate the prevalence of evidence-based medical treatment prescription and titration, as well as the causes of its underuse, in a broad real-world population of consecutive patients with HF across the whole ejection fraction spectrum and among different clinical phenotypes. Methods: The OPTIPHARM-HF registry (NCT06192524) is a prospective, multicenter, observational, national study of adult patients with symptomatic HF, as defined by current international guidelines, regardless of ejection fraction. Both outpatients and inpatients with chronic and acute decompensated HF will be recruited. The study will enroll up to 2500 patients with chronic HF at approximately 35 Italian HF centres. Patients will be followed for a maximum duration of 24 months. The primary objective of the OPTIPHARM-HF registry is to assess prescription and adherence to evidence-based guideline-directed medical therapy (GDMT) in patients with HF. The primary outcome is to describe the prevalence of GDMT use according to target guideline recommendation. Secondary objectives include implementation of comorbidity treatment, evaluation of sequence of treatment introduction and up-titration, description of GDMT implementation in the specific HF population, main causes of GDMT underuse, and assessment of cumulative rate of cardiovascular events. Conclusion: The OPTIPHARM-HF registry will provide important implications for improving patient care and adoption of recommended medical therapy into clinical practice among HF patients.

OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM‐HF registry / R.M. Inciardi, M. Vaduganathan, C.M. Lombardi, C. Gussago, P. Agostoni, P. Ameri, N. Aspromonte, L. Calò, M. Cameli, E. Carluccio, S. Carugo, M. Cipriani, R. De Caterina, G.M. De Ferrari, M. Emdin, A. Fornaro, M. Guazzi, M. Iacoviello, M. Imazio, M.T. La Rovere, S. Leonardi, M. Maccallini, D. Masarone, L. Moschini, A. Palazzuoli, G. Patti, R.F.E. Pedretti, P. Perrone Filardi, M.F. Piepoli, L. Potena, A. Salzano, A. Sciacqua, M. Senni, G. Sinagra, C. Specchia, S. Taddei, D. Vizza, G. Savarese, G. Rosano, M. Volterrani, M. Metra. - In: EUROPEAN JOURNAL OF HEART FAILURE. - ISSN 1388-9842. - (2024), pp. 1-8. [Epub ahead of print] [10.1002/ejhf.3260]

OPTImal PHARMacological therapy for patients with heart failure: Rationale and design of the OPTIPHARM‐HF registry

C. Gussago;P. Agostoni;S. Carugo;M. Guazzi;M.F. Piepoli;
2024

Abstract

Aims: Patients with heart failure (HF) remain often undertreated for multiple reasons, including treatment inertia, contraindications, and intolerance. The OPTIimal PHARMacological therapy for patients with Heart Failure (OPTIPHARM-HF) registry is designed to evaluate the prevalence of evidence-based medical treatment prescription and titration, as well as the causes of its underuse, in a broad real-world population of consecutive patients with HF across the whole ejection fraction spectrum and among different clinical phenotypes. Methods: The OPTIPHARM-HF registry (NCT06192524) is a prospective, multicenter, observational, national study of adult patients with symptomatic HF, as defined by current international guidelines, regardless of ejection fraction. Both outpatients and inpatients with chronic and acute decompensated HF will be recruited. The study will enroll up to 2500 patients with chronic HF at approximately 35 Italian HF centres. Patients will be followed for a maximum duration of 24 months. The primary objective of the OPTIPHARM-HF registry is to assess prescription and adherence to evidence-based guideline-directed medical therapy (GDMT) in patients with HF. The primary outcome is to describe the prevalence of GDMT use according to target guideline recommendation. Secondary objectives include implementation of comorbidity treatment, evaluation of sequence of treatment introduction and up-titration, description of GDMT implementation in the specific HF population, main causes of GDMT underuse, and assessment of cumulative rate of cardiovascular events. Conclusion: The OPTIPHARM-HF registry will provide important implications for improving patient care and adoption of recommended medical therapy into clinical practice among HF patients.
Cardiovascular outcomes; Guideline‐directed medical therapy; Heart failure;
Settore MED/11 - Malattie dell'Apparato Cardiovascolare
2024
23-giu-2024
Article (author)
File in questo prodotto:
File Dimensione Formato  
Optimal.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 499.66 kB
Formato Adobe PDF
499.66 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1075048
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact